Congestive Heart FailureSchlaHFNCT01500759
Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry
An observational study of Congestive Heart Failure and Left Ventricular Systolic Dysfunction, run by ResMed at 199 sites in 2 countries.
Trial summary
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Congestive Heart Failure, Left Ventricular Systolic Dysfunction
- How many people
- 6,876 participants
- Where
- 199 sitesin 2 countries
- Study dates
- Nov 2007to May 2013
- How long will I take part?
- 4 Weeks
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with Chronic Heart Failure with LVEF ≤ 45% and NYHA III-IV or NYHA class II with at least one hospitalisation for HF in the last 24 months.
Who may be able to join
- Patients must be over 18
- Chronic heart failure (at least 12 weeks since diagnosis) according to the current applicable guidelines
- Left ventricular systolic dysfunction (LVEF ≤ 45% by imaging method such as echocardiography, radionuclide angiography, left ventriculography, or cardiac magnetic resonance imaging) documented less than 12 weeks
- NYHA class III or IV at the time of inclusion or NYHA class II with at least one hospitalisation for HF in the last 24 months
- Patient is able to fully understand study information and signed informed consent
Who cannot join
- Life expectancy < 1 year for diseases unrelated to chronic HF
- Cardiac surgery, Percutaneous coronary intervention (PCI), Myocardial Infarction (MI) or unstable angina within 6 months
- CRT-implantation (either CRT-D or CRT-P) scheduled or within 6 months
- Transient ischemic attack (TIA) or Stroke within 3 months
- Hemodynamically significant uncorrected primary valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery
- Acute myocarditis/pericarditis within 6 months
- Current CPAP or bilevel therapy
Trial locations and contacts
199 sites in 2 countries.
199 sites in 2 countries
Germany192 sites
Praxis Dr. Frieske
Aachen, 52062
Universitätsklinikum Aachen
Aachen, 52074
DRK Krankenhaus
Alzey, 55232
Gemeinschaftspraxis Weiß/ Dr. Heesing
Arnsberg, 59821
Zentralklinikum Bad Berka
Bad Berka, 99437
Herzzentrum Bad Krozingen
Bad Krozingen, 79189
Klinik Lazariterhof
Bad Krozingen, 79189
Praxis Dr. Bauer
Bad Mergentheim, 97980
HDZ NRW
Bad Oeynhausen, 32545
Kardiologische Praxis Dr. Stroh
Bad Wurzach, 88410
Oberlausitz-Kliniken gGmbH
Bautzen, 02625
Kardiopraxis Rheinberg
Bergisch Gladbach, 51465
Charité Campus Mitte CCM
Berlin, 10117
Charité Campus Mitte
Berlin, 10117
Praxis Gemeinschaft Frille
Berlin, 10178
POLIKUM Friedenau
Berlin, 12157
Gemeinschaftspraxis Groß-Ziethener Chaussee
Berlin, 12355
Unfallkrankenhaus Berlin
Berlin, 12683
Jüdisches Krankenhaus Berlin
Berlin, 13347
Charité Campus Virchow Klinikum
Berlin, 13353
Charité Campus Virchow-Klinikum
Berlin, 13353
Praxis Westend
Berlin, 14050
Herzzentrum Brandenburg
Bernau, 16321
Praxis für Lunge,Herz und Schlaf
Bielefeld, 33617
Kardiologie Gemeinschaftspraxis Dr. Tenholt
Bochum, 44787
Universitätsklinikum Bergmannsheil
Bochum, 44789
Augusta Krankenanstalten Bochum
Bochum, 44791
St.-Josephs-Hospital
Bochum, 44791
Kardiologie Kemnade
Bochum, 44797
Kardiologische Praxis Dr. Staubach
Bochum, 44866
Praxis für Kardiologie Bonn
Bonn, 53127
Universitätsklinikum Bonn
Bonn, 53127
Kardiologische Praxis Marschner
Bonn, 53225
Gemeinschaftspraxis Kardiologie
Bottrop, 46236
Gemeinschaftspraxis Dres. Tinnefeld
Bottrop, 46240
Kardiologie Bühl
Brühl, 50321
Mediclin Rehazentrum Spreewald
Burg, 03096
Gemeinschaftspraxis Kardiologie Dr. Becker
Castrop-Rauxel, 44575
Kardiologische Praxis Dr. Isbruch
Castrop-Rauxel, 44577
MVZ am Küchwald
Chemnitz, 09113
Klinikum Coburg GmbH
Coburg, 96450
St.-Vinzenz Hospital
Cologne, 50733
Kardiologische Praxis Dr. Fritsch
Cologne, 50737
Malteser Krankenhaus St. Hildegardis
Cologne, 50931
Klinikum der Universität zu Köln- Herzzentrum
Cologne, 50937
Prof. Franzen Institut
Cologne, 50937
Universitätsklinikum Köln-Herzzentrum
Cologne, 50937
Praxis Dr. Anselm Bäumer
Cologne, 51065
Gemeinschaftspraxis Dres. Gysan/Heinzler/May
Cologne, 51105
Fachkrankenhaus Coswig
Coswig, 01640
Carl-Thiem-Klinikum gGmbH
Cottbus, 03042
Praxis Dr. Hecker
Dortmund, 44135
Kardiologie - Gemeinschaftspraxis Dortmund
Dortmund, 44137
Kardiologie-Gemeinschaftspraxis Dortmund
Dortmund, 44137
Kardiologische Praxis Dr. Golling
Dortmund, 44137
Klinikum Dortmund gGmbH
Dortmund, 44137
Clinical Trial Site Services
Dortmund, 44141
Kardiologische Praxis Dr. Wetzel
Dortmund, 44141
Kardiologische Praxis Dr. Lodde
Dortmund, 44147
Kardiologische Praxis Dr. Dröse
Dortmund, 44263
Facharztzentrum Dresden-Neustadt GbR
Dresden, 01099
Gemeinschaftpraxis Dres. Schmidt/Gronke
Dresden, 01219
Praxis Dr. Hohensee
Dresden, 01277
Herzzentrum Universität Dresden
Dresden, 01307
goMedus Gesundheitszentrum
Düsseldorf, 40212
Kardiologische Praxis Dr. Horowitz
Düsseldorf, 40215
Kardiologische Praxis Dr. Raff
Düsseldorf, 40237
Florence-Nightingale Krankenhaus
Düsseldorf, 40489
Khs Florence-Nightingale
Düsseldorf, 40489
Kardiologie Oberkassel
Düsseldorf, 40545
Gemeinschaftspraxis PD Dr. Lankisch
Düsseldorf, 40597
Fachärzte für Innere Medizin Dres Ritter, Richter, Mehrer, Kahl
Emmendingen, 79312
Helios Klinikum Erfurt-Kardiologie
Erfurt, 99089
Helios Klinikum Erfurt-Schlafmedizin
Erfurt, 99089
Universitätsklinikum Erlangen
Erlangen, 91054
Westdeutsches Herzzentrum, Universitätsklinikum Essen
Essen, 45122
Kardiologische Praxis Dr. Cord Müller
Essen, 45131
Schwerpunktpraxis Kardiologie Drs. Ophoff/Fritzsch
Essen, 45131
Kardiologische Praxis Prof. Winter
Essen, 45134
Kardiologie Praxis Dr. Bonnekamp
Essen, 45136
Praxis Dr. Tekiyeh
Essen, 45136
Elisabeth-Krankenhaus Essen
Essen, 45138
Ruhrlandklinik Essen
Essen, 45239
Praxis Dr. Rau
Essen, 45276
Kath. Kliniken Essen / Philippusstift
Essen, 45359
Gemeinschaftspraxis Dres. Guckenbiehl
Flonheim, 55237
Kardiologische Praxis Dr. Kruse
Forst, 03149
CardioVasculäres Centrum Frankfurt
Frankfurt, 60389
Praxis Dr. Diedrichs
Frechen, 50226
Universitaetsklinikum Freiburg
Freiburg im Breisgau, 79106
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79106
Gemeinschaftspraxis Dres. Böhmeke/Schmidt
Gladbeck, 45964
Kardiologische Praxis Dr. Hug
Günzburg, 89312
Kardiologische Praxis Gütersloh
Gütersloh, 33330
Gemeinschaftspraxis Dres Leischik/Littwitz
Hagen, 58095
Kardiologische Praxis Dr. Arens
Hagen, 58095
Gemeinschaftspraxis Dres. Subin/Lutter
Hamburg, 20095
Universitätsklinikum Hamburg-Eppendorf
Hamburg, 20246
Asklepios Klinik Barmbek
Hamburg, 22291
Internistenpraxis Alstertal Hamburg
Hamburg, 22399
Kardiologische Praxis Dr. Schröder
Hamburg, 22765
Kardiologische Praxis Dr. Cierpka
Hanover, 30159
Praxis Dr. Hötte
Hanover, 30449
Siloah Krankenhaus
Hanover, 30449
Kardiologische Praxis Dr. Hartung
Hanover, 30559
Heidelberger Praxisklinik für Kardiologie
Heidelberg, 69115
Praxis Dr. Durak
Heidelberg, 69115
Universitätsklinikum Heidelberg
Heidelberg, 69120
Thoraxklinik Heidelberg gGmbH
Heidelberg, 69126
Evangelisches Krankenhaus Herne
Herne, 44623
EvK Herne
Herne, 44623
Kardiologische Praxis Dr. Furche
Herne, 44623
Gemeinschaftspraxis Dr. Bruch
Herne, 44629
Kardiologische Praxis Dr. Schlichting
Herne, 44649
St. Elisabeth-Hospital Herten gGmbH
Herten, 45699
Praxis für Innere Medizin/Kardiologie
Hoyerswerda, 02977
Cardiopraxis Ingelheim
Ingelheim, Rhineland-Palatinate, 55218
Gemeinschaftspraxis Dres. Dobler/Turin
Karlstadt am Main, 97753
Ambulantes Herzzentrum Kassel
Kassel, 34121
Kardiologische Praxis Dr. Siegfried Frickel
Kempen, 47906
Klinik Kitzinger Land
Kitzingen, 97318
Klinikum Dahme-Spreewald GmbH
Königs Wusterhausen, 15711
Praxis Dr. Krater
Krefeld, 47799
Helios Klinikum Krefeld
Krefeld, 47805
Universitätsklinikum Leipzig-Herzzentrum
Leipzig, 04289
Helios Krankenhaus Leisnig
Leisnig, 04703
Gemeinschaftspraxis Dr. Hilgedieck/Sava
Lengerich, 49525
Kardiologische Praxis Dr. Faber
Lindlar, 51784
Ärztezentrum Holthausen-Biene
Lingen, 49808
Universitätsklinikum Schleswig-Holstein Campus Lübeck-Kardiologie
Lübeck, 23538
Kardiologische Praxis Ludwigsburg
Ludwigsburg, 71634
Klinikum der Johannes Gutenberg-Universität Mainz
Mainz, 55101
Gemeinschaftspraxis Dres. Heifer/Loster/Schernus
Mannheim, 68161
Gemeinschaftspraxis für Herz & Gefäße
Mannheim, 68161
Universitätsklinik Mannheim-Kardiologie
Mannheim, 68167
Gemeinschaftspraxis Dres. Brandt / Jakobs
Mannheim, 68305
Universitätsklinikum Gießen/Marburg Standort Marburg-Kardiologie
Marburg, 35043
Praxis Dr. Schnabel
Meissen, 01662
Gemeinschaftspraxis Dr. Jocham
Memmingen, 87700
Praxis für Kardiologie Dr. med. Menz
Menden, 58706
Herz-& Gefäßpraxis
Metzingen, 72555
Praxis Kutenhausen
Minden, 32425
Krankenhaus Bethanien
Moers, 47441
Kardiologische Praxis Dr. Schön
Mühldorf, 84453
Evangelisches Krankenhaus Mülheim
Mülheim, 45468
Kardiologie am Rotkreuzplatz
München, 80634
Gemeinschaftspraxis Dres. Wauer / Windstetter
München, 80799
Kardiologische Praxis Dr. Herholz
München, 80809
Klinikum Augustinum München
München, 81375
Praxis Dres. Böhme/Linke
München, 81667
Kardiologische Praxis Dr. Muradi
Münster, 29633
Universitätsklinikum Münster
Münster, 48149
Praxis für Kardiologie Dr. med. Hewing
Münster, 48151
Städtisches Khs Lukas
Neuss, 41472
Kardiologische Praxis Nienburg
Nienburg, 31582
Klinikum Nürnberg Süd
Nuremberg, 90471
Kardiologische Praxis Dr. Gumbrecht
Ochtrup, 48607
Kardiologische Praxis Dr. Hassler
Plauen, 8523
Kardiologische Praxis Dr. Wiethölter
Radebeul, 01445
Praxis für Kardiologie Ratingen
Ratingen, 40878
Praxis Dr. Fröhlich
Ratingen, 40885
DRK Krankenhaus Mölln-Ratzeburg
Ratzeburg, 23909
Ambulantes Cardiovaskuläres Centrum
Ravensburg, 88212
Gemeinschaftspraxis Dr. Weber/Dr. Feja
Recklinghausen, 45657
Universitätsklinikum Regensburg
Regensburg, 93053
Khs St. Adolf Stift
Reinbek, 21465
Praxis Dr. Hein
Reinbek, 21465
Kardiologische Praxis Dr. Kleinz
Remscheid, 42853
Praxis Dr. Nebel
Rheine, 48429
Praxis Dr. Kestermann
Rheine, 48431
Kardiologische Praxis Dr. Figura
Rinteln, 31737
Praxis Dr. Ebeling
Schönefeld, 12529
Kardiologische Praxis Dr. Heinze
Schwerte, 58239
Praxisgemeinschaft Cardio-Soest
Soest, 59494
Facharztzentrum Sonneberg
Sonneberg, 96515
Kreiskrankenhaus Stollberg GmbH
Stollberg, 09366
Kardiologische Praxis Dr. Birkenhagen
Stollberg, 9366
Klinikum Uelzen GmbH
Uelzen, 29525
Herzklinik Ulm Dr. Haerer und Partner
Ulm, 89077
Zentrum für Innere Medizin Uni Ulm
Ulm, 89081
Katharinen Hospital Unna
Unna, 59423
Kardiologische Praxis Dr. Burkhard-Meier
Viersen, 41747
Praxis Dr. Gerritsen
Waldkraiburg, 84478
Fachkliniken Wangen
Wangen, 88239
Stiftungsklinik Weißenhorn
Weißenhorn, 89264
Kardiologisch angiologische Gemeinschaftspraxis
Wiesbaden, 65183
Kardiologische Gemeinschaftspraxis Dr. K. Vorbeck
Wiesbaden, 65183
Kardiologische Praxis Dr. Vrettos
Witten, 58452
Kardiologische Praxis Dr. Rudolf/ Dr. Bernhardt
Worms, 67547
Comprehensive Heart Failure Center, Universitätsklinikum Würzburg
Würzburg, 97080
Universitätsklinikum Würzburg
Würzburg, 97080
Evangel. Khs Zweibrücken
Zweibrücken, 66482
Australia7 sites
Royal Adelaide Hospital
Adelaide, South Australia, 5000
Rivercity Private Hospital
Auchenflower, Queensland, 4066
Melbourne Sleep Disorders Centre
East Melbourne, Victoria 3002, 3002
Baker IDI Heart and Diabetes Institute
Melbourne, Victoria, 3004
St Vincents and Mercy Private Hospital
Melbourne, Victoria, 3065
Hollywood Private Hospital (CVS)
Nedlands, Western Australia, 6009
Westmead Hospital
Westmead, New South Wales, 2145
About this study
Official title: Prevalence, Clinical Characteristics and Type of Sleep-disordered Breathing in Patients With Chronic, Symptomatic, Systolic Heart Failure
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb.
For this purpose data from patients suffering from chronic, symptomatic heart failure with impaired left ventricular ejection fraction will be collected prospectively.
Read the detailed description
Despite recent advances in pharmacological treatment, congestive heart failure (CHF) continues to cause debilitating symptoms, frequent hospital admissions and a high mortality. Despite of therapy with beta-blockers and ACE-inhibitors many patients have persistent symptoms and most will eventually die of cardiovascular causes, often from progressive heart failure.
Sleep Disordered Breathing (SDB) is known to cause consequences, which have negative effects on heart failure.
Objective target of the registry is to investigate the prevalence of SDB, clinical characteristics, symptoms and the degree and type of SDB in patients with chronic HF.
For this purpose data from patients with chronic heart failure will be collected prospectively.In the registry several cardiologists in private practice or hospital and cooperating sleep laboratories shall participate.
Cardiologists screen patients with Chronic Heart Failure (chronic HF) prospectively. In case of suffering from chronic HF for at least 12 weeks since diagnosis, with NYHA III-IV or NYHA class II with at least one hospitalisation for HF in the last 12 months. Written informed consent for data privacy aspects must be obtained before screening for SDB. Patients who satisfy to all inclusion- and exclusion criteria will be included consecutively into the registry.
- Keywords
- chronic heart failure, heart failure, hf, sleep-disordered breathing, sdb, nyha, lvef, cheyne stokes, central sleep apnoea, sleep apnoea
- Medical subject headings
- Heart Failure, Ventricular Dysfunction, Left, Sleep Apnea Syndromes, Cheyne-Stokes Respiration, Sleep Apnea, Central
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of SDB in Chronic HF Patients
SDB= Sleep disordered breathing; HF= Heart failure
Measured: 1 night: Patients fulfilling the inclusion and exclusion criteria were examined for sleep-disordered breathing during 1 night in a sleep facility
Secondary outcomes (22)
Left Ventricular Ejection Fraction
Amount of blood in the left ventricle at the end of Diastole that is being pumped into the System during systole
Measured: 1 night: Patients fulfilling the inclusion and exclusion criteria were examined for LVEF in a medical institution
Age
Age years
Measured: 1-time single assessment at baseline
Body Mass Index
Measured: 1-time single assessment at baseline
Male Gender
Measured: 1-time single assessment at baseline
NYHA Class ≥III
New York Heart Association Class III: Marked Limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in undue breathlessness, fatigue or palpitations.
Measured: At baseline, the NYHA was determined in a medical institution or taken restrospectively from medical records
Ischemic Etiology
Ischemic etiology describes a condition where a weakening or disease of the heart muscle is caused by reduced supply of blood (underlying cause might be the coronary artery). Secondary outcome ischemic etiology describes the cause of heart failure (HF) "ischemic" in HF patients without and with sleep-disordered breathing in percent of the respective study arm/group: e.g. x% of patients without SDB have HF with an ischemic etiology.
Measured: 1-time: At baseline the ischemic etiology was determined in the medical institution or taken retrospectively from the medical records.
Atrial Fibrillation
Measured: 1-time: At baseline atrial fibrillation (AF) was determined in the medical institution or AF history was taken retrospectively from the medical records
Nocturnal Dyspnea
Measured: 1-time: At baseline history of nocturnal dyspnea taken retrospectively from the medical records
Nocturia ≥3 Times/Night
Measured: 1-time: At baseline nocturia was assessed 1 time (anamnesis)
Apnoea-Hypopnea-Index
Number of Apnoeas (cessation of airflow for at least 10 seconds) and hypopneas (reduced airflow for at least 10 seconds) per hours of sleep
Measured: 1 night: Apnoea-Hypopnea Index (AHI) was assessed during one night under polysomnography (PSG) in a sleep facility
Oxygen Desaturation Index
Number of times that arterial blood oxygen saturation Drops by ≥3% from the Basic value.
Measured: 1 time: Oxygen desaturation Index (ODI) was assessed during one night under polysomnography (PSG) in a sleep facility
Mean SpO2
Saturation of oxygen
Measured: 1 night: oxygen saturation was assessed during one night under polysomnography (PSG) in a sleep facility
Min SpO2
Lowest Saturation with oxygen
Measured: 1 night: Minimum saturation with oxygen was assessed during one night under polysomnography (PSG) in a sleep facility
Medication ACE Inhibitors and/ARBs
ACE: Angiotensin converting Enzyme; ARB Angiotension receptor blocker
Measured: 1-time: At baseline medication was assessed 1 time (anamnesis)
Beta-blocker
Measured: 1-time: At baseline medication was assessed 1 time (anamnesis)
Diuretics
Measured: 1-time: At baseline medication was assessed 1 time (anamnesis)
Digitalis
Measured: 1-time: At baseline medication was assessed 1 time (anamnesis)
Aldosterone Antagonists
Measured: 1-time: At baseline medication was assessed 1 time (anamnesis)
Male Gender as Predictor for SDB in Chronic HF
From the total number of participants, the number of male patients without and with SDB were counted and an odds Ratio for male sex as predictor for SDB in chronic heart failure
Measured: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Atrial Fibrillation (AF) as a Predictor for SDB in Chronic HF
From the total number of participants, the number of male patients without and with SDB were counted and an odds ratio calculated for AF as predictor for SDB in chronic heart failure
Measured: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Ischemic Etiology as Predictor for SDB in Chronic HF
From the total number of participants, the number of male patients without and with SDB were counted and an odds ratio calculated for ischemic etiology as predictor for SDB in chronic heart failure
Measured: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
NYHA Class >= III as Predictor for SDB in Chronic HF
From the total number of participants, the number of male patients without and with SDB were counted and an odds ratio calculated for NYHA (New York Heart Association - class I not impaired, class II slighly impaired, class III severly impaired, class IV = unable to perform normal tasks) class≥III as predictor for SDB in chronic heart failure
Measured: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Dec 2011 (estimated)
- Study startNov 2007
- Primary completionMay 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Congestive Heart FailureStudies of the same condition, open and under way.
- More trials run by ResMedThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 6,876 participants (actual)
- Target duration
- 4 Weeks
Sponsor and investigators
- Lead sponsor
- ResMed
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Erland Erdmann, Prof, Principal investigator, Klinikum der Universität zu KölnHelmut Teschler, Prof, Principal investigator, Ruhrlandklinik EssenHolger Woehrle, MD, Study director, ResMed
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01500759
- Sponsor's protocol ID
- 001
- Acronym
- SchlaHF
- Status last verified
- May 2020
- First submitted
- 23 Dec 2011
- Last updated
- 9 Jul 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Woehrle H, Oldenburg O, Arzt M, Graml A, Erdmann E, Teschler H, Wegscheider K; SCHLA-HF Investigators. Determining the prevalence and predictors of sleep disordered breathing in patients with chronic heart failure: rationale and design of the SCHLA-HF registry. BMC Cardiovasc Disord. 2014 Apr 9;14:46. doi: 10.1186/1471-2261-14-46.
PubMed 24716484Arzt M, Woehrle H, Oldenburg O, Graml A, Suling A, Erdmann E, Teschler H, Wegscheider K; SchlaHF Investigators. Prevalence and Predictors of Sleep-Disordered Breathing in Patients With Stable Chronic Heart Failure: The SchlaHF Registry. JACC Heart Fail. 2016 Feb;4(2):116-125. doi: 10.1016/j.jchf.2015.09.014. Epub 2015 Dec 9.
PubMed 26682790Arzt M, Oldenburg O, Graml A, Erdmann E, Teschler H, Wegscheider K, Suling A, Woehrle H; SchlaHF Investigators. Phenotyping of Sleep-Disordered Breathing in Patients With Chronic Heart Failure With Reduced Ejection Fraction-the SchlaHF Registry. J Am Heart Assoc. 2017 Nov 29;6(12):e005899. doi: 10.1161/JAHA.116.005899.
PubMed 29187390
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence, Clinical Characteristics and Type of Sleep-disordered Breathing in Patients With Chronic, Symptomatic, Systolic Heart Failure
- ClinicalTrials.gov ID
- NCT01500759
- Acronym / sponsor ID
- SchlaHF / 001
- Keywords
- chronic heart failure, heart failure, hf, sleep-disordered breathing, sdb, nyha, lvef, cheyne stokes
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 6,876 participants (actual)
- Lead sponsor
- ResMedIndustry (pharma, biotech, devices)
- Study start
- Nov 2007
- Primary completion
- May 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 28 Dec 2011 (estimated)
- Results
- Posted 9 Jul 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective target of the registry is to investigate the prevalence of SDB as well as the clinical characteristics of patients with and without SDB as well as the predominant type of sdb.
For this purpose data from patients suffering from chronic, symptomatic heart failure with impaired left ventricular ejection fraction will be collected prospectively.
Detailed description
Despite recent advances in pharmacological treatment, congestive heart failure (CHF) continues to cause debilitating symptoms, frequent hospital admissions and a high mortality. Despite of therapy with beta-blockers and ACE-inhibitors many patients have persistent symptoms and most will eventually die of cardiovascular causes, often from progressive heart failure.
Sleep Disordered Breathing (SDB) is known to cause consequences, which have negative effects on heart failure.
Objective target of the registry is to investigate the prevalence of SDB, clinical characteristics, symptoms and the degree and type of SDB in patients with chronic HF.
For this purpose data from patients with chronic heart failure will be collected prospectively.In the registry several cardiologists in private practice or hospital and cooperating sleep laboratories shall participate.
Cardiologists screen patients with Chronic Heart Failure (chronic HF) prospectively. In case of suffering from chronic HF for at least 12 weeks since diagnosis, with NYHA III-IV or NYHA class II with at least one hospitalisation for HF in the last 12 months. Written informed consent for data privacy aspects must be obtained before screening for SDB. Patients who satisfy to all inclusion- and exclusion criteria will be included consecutively into the registry.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 4 Weeks
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with Chronic Heart Failure with LVEF ≤ 45% and NYHA III-IV or NYHA class II with at least one hospitalisation for HF in the last 24 months.
Key inclusion criteria (5 listed)
- Patients must be over 18
- Chronic heart failure (at least 12 weeks since diagnosis) according to the current applicable guidelines
- Left ventricular systolic dysfunction (LVEF ≤ 45% by imaging method such as echocardiography, radionuclide angiography, left ventriculography, or cardiac magnetic resonance imaging) documented less than 12 weeks
- NYHA class III or IV at the time of inclusion or NYHA class II with at least one hospitalisation for HF in the last 24 months
- Patient is able to fully understand study information and signed informed consent
Key exclusion criteria (7 listed)
- Life expectancy < 1 year for diseases unrelated to chronic HF
- Cardiac surgery, Percutaneous coronary intervention (PCI), Myocardial Infarction (MI) or unstable angina within 6 months
- CRT-implantation (either CRT-D or CRT-P) scheduled or within 6 months
- Transient ischemic attack (TIA) or Stroke within 3 months
- Hemodynamically significant uncorrected primary valvular heart disease, obstructive or regurgitant, or any valvular disease expected to lead to surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of SDB in Chronic HF Patients
Time frame: 1 night: Patients fulfilling the inclusion and exclusion criteria were examined for sleep-disordered breathing during 1 night in a sleep facility
SDB= Sleep disordered breathing; HF= Heart failure
22 secondary outcomes
Left Ventricular Ejection Fraction
Time frame: 1 night: Patients fulfilling the inclusion and exclusion criteria were examined for LVEF in a medical institution
Age
Time frame: 1-time single assessment at baseline
Body Mass Index
Time frame: 1-time single assessment at baseline
Male Gender
Time frame: 1-time single assessment at baseline
NYHA Class ≥III
Time frame: At baseline, the NYHA was determined in a medical institution or taken restrospectively from medical records
Ischemic Etiology
Time frame: 1-time: At baseline the ischemic etiology was determined in the medical institution or taken retrospectively from the medical records.
Atrial Fibrillation
Time frame: 1-time: At baseline atrial fibrillation (AF) was determined in the medical institution or AF history was taken retrospectively from the medical records
Nocturnal Dyspnea
Time frame: 1-time: At baseline history of nocturnal dyspnea taken retrospectively from the medical records
Nocturia ≥3 Times/Night
Time frame: 1-time: At baseline nocturia was assessed 1 time (anamnesis)
Apnoea-Hypopnea-Index
Time frame: 1 night: Apnoea-Hypopnea Index (AHI) was assessed during one night under polysomnography (PSG) in a sleep facility
Oxygen Desaturation Index
Time frame: 1 time: Oxygen desaturation Index (ODI) was assessed during one night under polysomnography (PSG) in a sleep facility
Mean SpO2
Time frame: 1 night: oxygen saturation was assessed during one night under polysomnography (PSG) in a sleep facility
Min SpO2
Time frame: 1 night: Minimum saturation with oxygen was assessed during one night under polysomnography (PSG) in a sleep facility
Medication ACE Inhibitors and/ARBs
Time frame: 1-time: At baseline medication was assessed 1 time (anamnesis)
Beta-blocker
Time frame: 1-time: At baseline medication was assessed 1 time (anamnesis)
Diuretics
Time frame: 1-time: At baseline medication was assessed 1 time (anamnesis)
Digitalis
Time frame: 1-time: At baseline medication was assessed 1 time (anamnesis)
Aldosterone Antagonists
Time frame: 1-time: At baseline medication was assessed 1 time (anamnesis)
Male Gender as Predictor for SDB in Chronic HF
Time frame: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Atrial Fibrillation (AF) as a Predictor for SDB in Chronic HF
Time frame: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Ischemic Etiology as Predictor for SDB in Chronic HF
Time frame: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
NYHA Class >= III as Predictor for SDB in Chronic HF
Time frame: 1-time: At baseline physical status was assessed 1 time (anamnesis and medical records)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 24716484Woehrle H, Oldenburg O, Arzt M, Graml A, Erdmann E, Teschler H, Wegscheider K; SCHLA-HF Investigators. Determining the prevalence and predictors of sleep disordered breathing in patients with chronic heart failure: rationale and design of the SCHLA-HF registry. BMC Cardiovasc Disord. 2014 Apr 9;14:46. doi: 10.1186/1471-2261-14-46.
- Results publication: PubMed 26682790Arzt M, Woehrle H, Oldenburg O, Graml A, Suling A, Erdmann E, Teschler H, Wegscheider K; SchlaHF Investigators. Prevalence and Predictors of Sleep-Disordered Breathing in Patients With Stable Chronic Heart Failure: The SchlaHF Registry. JACC Heart Fail. 2016 Feb;4(2):116-125. doi: 10.1016/j.jchf.2015.09.014. Epub 2015 Dec 9.
- Results publication: PubMed 29187390Arzt M, Oldenburg O, Graml A, Erdmann E, Teschler H, Wegscheider K, Suling A, Woehrle H; SchlaHF Investigators. Phenotyping of Sleep-Disordered Breathing in Patients With Chronic Heart Failure With Reduced Ejection Fraction-the SchlaHF Registry. J Am Heart Assoc. 2017 Nov 29;6(12):e005899. doi: 10.1161/JAHA.116.005899.
Related trials for Congestive Heart Failure
Active, not recruiting
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
Heart Failure, Congestive Heart Failure
RecruitingPhase 4
DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure
Pulmonary Edema, Congestive Heart Failure
Recruiting
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall
Recruiting
Peripheral Venous Pressure (PVP) Trial
Congestive Heart Failure
Not yet recruiting
Digital Outreach for Heart Failure Adherence
CHF - Congestive Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Erland Erdmann, Prof principal investigator
Klinikum der Universität zu Köln
Helmut Teschler, Prof principal investigator
Ruhrlandklinik Essen
Holger Woehrle, MD study director
ResMed
199 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Congestive Heart Failure and Left Ventricular Systolic Dysfunction, run by ResMed at 199 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 199 sites in Germany, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of SDB in Chronic HF Patients (time frame: 1 night: Patients fulfilling the inclusion and exclusion criteria were examined for sleep-disordered breathing during 1 night in a sleep facility). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01500759, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2020; AzTrials last refreshed its copy on 6 Nov 2026.